Advertisement
Document › Details
GlaxoSmithKline plc. (7/12/18). "Press Release: James Ford Appointed GSK General Counsel". London.
Organisation | GlaxoSmithKline plc (LSE: GSK, NYSE: GSK) | |
Today | GSK plc (LSE: GSK, NYSE: GSK) | |
Group | GSK (Group) | |
Product | legal services | |
Product 2 | pharmaceutical | |
GSK today announced that James Ford, currently SVP and General Counsel for Global Pharma, will succeed Dan Troy as General Counsel, GSK. James will join the Corporate Executive Team (CET) on 1 August.
Through his 23-year career with GSK, James has gained wide-ranging legal experience including investigations, complex corporate transactions and litigation in senior roles across the USA, Asia and UK.
James replaces Dan Troy who will leave GSK after 10 years as General Counsel.
GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
For further information please visit www.gsk.com/about-us
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2017.
Record changed: 2023-06-05 |
Advertisement
More documents for GSK (Group)
- [1] Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion"....
- [2] GSK plc. (1/9/24). "Press Release: GSK Enters Agreement to Acquire Aiolos Bio"....
- [3] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
- [4] GSK plc. (12/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20093". London....
- [5] Aiolos Bio, Inc.. (10/24/23). "Press Release: Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody". San Francisco, CA & London....
- [6] GSK plc. (10/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20089". London....
- [7] LimmaTech Biologics AG. (7/20/23). "Press Release: GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine". Schlieren....
- [8] GSK plc. (6/28/23). "Press Release: GSK Completes Acquisition of Bellus Health [For media and investors only]". London....
- [9] GSK plc. (4/18/23). "Press Release: GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company Bellus Health [For media and investors only]". London....
- [10] CureVac N.V.. (1/6/23). "Press Release: CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs". Tübingen & Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top